glp-1 latest Poll: 1 in 8 Adults Say They Are Currently Taking a Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford GLP-1 Trends June 2025: Why

The FDA label lists Type 2 diabetes and cardiovascular risk reduction in adults with Type 2 diabetes and established cardiovascular disease as approved uses

23 This need for injection can limit patient use and may also restrict the possibility of combining these drugs in fixed-dose treatments with other therapies for cardio-metabolic conditions

GLP-1 drugs like semaglutide work through multiple pathways: they reduce appetite and body weight, improve insulin sensitivity, and directly influence how your liver produces cholesterol and triglycerides

you are meeting protein and hydration targets without difficulty

The GLP-1 revolution is therefore not just about losing weightit is about reshaping the economics of health, nutrition, and consumer behaviour on a global scale